High-dose recombinant interleukin-2 alone: a regimen with limited activity in the treatment of advanced renal cell carcinoma.

Abrams, J S; Rayner, A A; Wiernik, P H; Parkinson, D R; Eisenberger, M; Aronson, F R; Gucalp, R; Atkins, M B; Hawkins, M J

Abrams, J S; Rayner, A A; Wiernik, P H; Parkinson, D R; Eisenberger, M; Aronson, F R; Gucalp, R; Atkins, M B; Hawkins, M J.

Affiliation

Abrams JS; Division of Medical Oncology, University of Maryland Cancer Center, Baltimore 21201.

J Natl Cancer Inst ; 82(14): 1202-6, 1990 Jul 18.

Article in En | MEDLINE | ID: mdl-2194036

Subject(s)

Carcinoma, Renal Cell/drug therapy; Interleukin-2/therapeutic use; Kidney Neoplasms/drug therapy; Adult; Aged; Carcinoma, Renal Cell/pathology; Carcinoma, Renal Cell/secondary; Clinical Trials as Topic; Drug Administration Schedule; Drug Evaluation; Female; Humans; Interleukin-2/administration & dosage; Kidney Neoplasms/pathology; Male; Middle Aged; Multicenter Studies as Topic; Recombinant Proteins/administration & dosage; Recombinant Proteins/therapeutic use

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Renal Cell / Interleukin-2 / Kidney Neoplasms Type of study: Clinical_trials / Prognostic_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: J Natl Cancer Inst Year: 1990 Type: Article

Search on Google

XML

PubMed Links